Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
to the presence or absence of these criteria: 63.4% (443/698) of patients were at very low risk (<1%), 30.7% (214/698) at low risk (<10%), and 5.9% (41/698) at high risk (>10%).

Conclusions: Safe selection for NAC for colon cancer can be informed by using two features that are available before treatment initiation and identify a small number of patients with high risk of preoperative obstruction.

Clinical trial identification: NCT00647530.

Legal entity responsible for the study: Birmingham Clinical Trials Unit, University of Birmingham.

Funding: FOxTROT is funded by Cancer Research UK. Additional support was provided by the Birmingham and Leeds Experimental Cancer Medicine Centres (ECMC) network, Royal College of Surgeons of England and Rosetrees Trust, and the Swedish Cancer Society.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.911

390MO Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada

M. Tehfe1, D. Charpentier1, M-F. Vachon1, M. Champagne2

1Hemato-oncology Department, CHUM - Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada; 2Hematology-Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada; *Hematology-Oncology, Hôpital de Verdun, Verdun, QC, Canada

Background: CRC, 3rd most common cancer in Quebec, is the 2nd and 3rd cause of cancer related death in men and women respectively. This study aimed to assess how the provincial screening program and CRC diagnosis were disrupted during the COVID-19 pandemic.

Methods: Ministry of Health of Quebec data related to cancer screening programs and diagnosis during the periods of March 2019 to February 2020 and March 2020 to February 2021 were recently reported (ISBN: 978-2-550-888179-1). We analyzed and compared this data related to Fecal Occult Blood Test (FOBT), colonoscopy, and CRC surgery rates for two comparative 4-month periods (April to July).

Results: Status of public health emergency was declared in Quebec on March 16, 2020. All elective procedures were therefore suspended on that date. From April to July 2020, FOBT decreased by 67.26%, colonoscopy procedures by 57.8% and CRC surgery by 29.5% compared to the same period from 2019. Peak of suspension of these activities was reached in April and May 2020. The waiting list for colon endoscopy increased by 210% from April to July 2020 and by 141% from August to July 2020, FOBT decreased by 67.26%, colonoscopy procedures by 57.8% and CRC surgery was reduced by 30% from April to July 2020 most probably because of a lower surgical referral.

Conclusions: The COVID-19 affected screening and lead to decreased CRC diagnosis rate. Even with the recovery to pre-pandemic activities, catching up with the delays is a challenge for health authorities. The impact of the offloading of diagnostic and surgical activities on cancer mortality is hard to be estimated but is likely to be significant.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.912

391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

E.S. Bergen1, N. Chrestou1, K. Le Malicet1, C. Canton2, M. Di Bartolomeo3, F. Galli4, F. Galli4, R. Labianca4, Q. Shi5, S.R. Alberts6, R.M. Goldberg7, C. Lepage8, F.A. Sincrope9, J. Tsaeb10

1Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; 2Department of Digestive Surgery, University Hospital of Limoges, France, Limoges, France; 3Biostatistics department, University of Burgundy and Franche Comté, Dijon, France; 4Hepato-Gastroenterology and Digestive Oncology Department, University of Burgundy and Franche Comté, Dijon, France; 5Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 7Medical Oncology Unit, Giovanni XXIII Hospital, Bergamo, Italy; 8Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA; 9Division of Oncology, Mayo Clinic, Rochester, MN, USA; 10Medicine, West Virginia University Cancer Institute, Virginia, VA, USA; 11Hepato-Gastroenterology and Digestive Oncology, CHU Dijon, Dijon, France; 12Gastroenterology and Digestive Oncology Department, Hospital European George Pompidou, Paris, France

Background: Obesity and diabetes mellitus type 2 are associated with an increased risk of colorectal cancer. Recent studies have suggested beneficial effects of metfor- min in patients with cancer and diabetes. We sought to investigate the impact of metformin on recurrence and survival in a large, pooled analysis of non-metastatic colon cancer (CC) patients.

Methods: A patient-level meta-analysis from three randomized adjuvant trials was performed. All patients had resection with curative intent of a stage II or III CC and were treated with standard fluoropyrimidine and oxaliplatin (+/- cetuximab). We investigated the impact of metformin on time to recurrence (TTR) and overall survival (OS). Multivariable analyses were adjusted for age, ECOG, T-stage, N-stage, grade, and primary tumor location.

Results: 5922 patients were available for this analysis with a median follow-up of 6.8 years. 621 of 5922 patients (10.5%) had diabetes at the time of their diagnosis of CC. Of those with diabetes, 327 (52.7%) were defined as metformin-users and 294 pa- tients (47.3%) as non-metformin-users. As expected, baseline characteristics associ- ated with diabetes differed between non-diabetic, metformin-diabetic and non- metformin-diabetic CC patients whereas tumor-related characteristics were shown to be well balanced. CC patients with diabetes had a significantly shorter median TTR (adjHR: 1.24; 95% CI, 1.13 to 1.4; p = 0.002) and median OS (adjHR: 1.77; 95% CI, 1.19 to 1.45; p = 0.003) compared to non-diabetic CC patients. Diabetic CC patients not receiving metformin had a significantly worse OS (adjHR: 1.41; 95% CI, 1.13 to 1.77; p = 0.017); however, use of metformin appeared to attenuate this effect on OS (adjHR: 1.18; 95% CI, 0.95 to 1.48; p = 0.017).

Conclusions: CC patients with diabetes type 2 had a significantly worse survival as well as shorter TTR. Furthermore, our data suggest that metformin may attenuate the detrimental effect of diabetes on CC patient outcomes.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.913

392P Integrating fragmentomic features for non-invasive early detection of colorectal advanced adenoma and adenocarcinoma

J. Peng1, W. Tang2, H. Bao2, S. Mo1, X. Ma1, R. Liu2, X. Chen3, S. Wu4, Y. Li1, L. Zhang1, F. Liu1, X. Wu1, Y. Shao1, S. Cai4

1Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; 4Translational Medicine Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China

Background: Previous studies on liquid biopsy-based detection of advanced colorectal adenoma (advCRA) and early stage adenocarcinoma (CRA) were limited by low sensitivity. To this end, we performed a prospective study and established an inte- grated model using multiple fragmentomic profiles of plasma cell-free DNA (cfDNA) for accurately and cost-effectively detecting stage 0/I CRC and advCRA.

Methods: This study enrolled a total of 621 participants, including 298 CRC patients (34 stage 0, 264 stage I), 92 advCRA patients and 231 healthy controls. cfDNA samples were prepared for low coverage whole-genome sequencing (~5X). Particip- ants were randomly divided into a training cohort (N = 310) and a test cohort (N = 311). An ensemble stacked model differentiating healthy controls from advCRA/CRC patients was trained using four machine learning models and fragmentomic features, including fragment size distribution and ratio, end and breakpoint motif, and copy number alteration, which was then validated in the test cohort.

Results: Our model showed an Area Under the Curve (AUC) of 0.988 for differenti- ating advCRA/CRC patients from healthy individuals. The model performed even better for identifying CRC patients (AUC 0.990) compared to advCRA patients (AUC 0.988).

https://doi.org/10.1016/j.annonc.2021.08.914

393P Integrating fragmentomic features for non-invasive early detection of colorectal advanced adenoma and adenocarcinoma

J. Peng1, W. Tang2, H. Bao2, S. Mo1, X. Ma1, R. Liu2, X. Chen3, S. Wu4, Y. Li1, L. Zhang1, F. Liu1, X. Wu1, Y. Shao1, S. Cai4

1Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; 4Translational Medicine Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China

Background: Previous studies on liquid biopsy-based detection of advanced colorectal adenoma (advCRA) and early stage adenocarcinoma (CRA) were limited by low sensitivity. To this end, we performed a prospective study and established an inte- grated model using multiple fragmentomic profiles of plasma cell-free DNA (cfDNA) for accurately and cost-effectively detecting stage 0/I CRC and advCRA.

Methods: This study enrolled a total of 621 participants, including 298 CRC patients (34 stage 0, 264 stage I), 92 advCRA patients and 231 healthy controls. cfDNA samples were prepared for low coverage whole-genome sequencing (~5X). Particip- ants were randomly divided into a training cohort (N = 310) and a test cohort (N = 311). An ensemble stacked model differentiating healthy controls from advCRA/CRC patients was trained using four machine learning models and fragmentomic features, including fragment size distribution and ratio, end and breakpoint motif, and copy number alteration, which was then validated in the test cohort.

Results: Our model showed an Area Under the Curve (AUC) of 0.988 for differenti- ating advCRA/CRC patients from healthy individuals. The model performed even better for identifying CRC patients (AUC 0.990) compared to advCRA patients (AUC 0.988).